IL18 and fatty liver disease: Exogenous IL-18 administration has been shown to counteract steatohepatitis in mice (Murphy et al., 2016), whereas IL-18-deficient mice exhibit hepatic steatosis and steatohepatitis (Lana et al., 2016; Netea et al., 2006; Yamanishi et al., 2016).